This Web Site is committed to the memory of Janis Morrow.
HCV News Archives
Index
2001-2002
JANUARY 2002/2001
Hepatzyme: Saftey Analysis of Phase I Study
Levothyroxine use could increase number of transplantable donor organs
Second group announces 'knock out' cloned pigs
Round Up the Unusual Suspects
Man who came out on public TV dies at 50 Lilly and Vertex Pharmaceuticals Select Novel Oral Anti-Hepatitis C Summary of FDA Peg-Intron Hearing Expanding the Donor Pool with Living Donors
Hepatitis C Research Gets a Boost
1F7 Shows Positive Data for Hepatitis Heavy Demand Strains Schering? First Monoclonal Antibody to Show Activity Against The Hep C Virus
Research To Understand Poor Outcome In African-Americans/Asian
Liver Transplants
Idun Pharmaceuticals' Clinical Trial Demonstrates Safety Of Liver
Disease Drug
Roche confident new data will let Pegasys drug fly
February
2002
2002Community Notice: Procedure to avoid missing
doses on the PEG-Intron Access Assurance Program
Amarillo Biosciences to Receive Patent on Solid Dosage Forms of
Interferon; Company Also Obtains Additional Funding Through Private
Placement
New Drugs for Treatment of Chronic Hepatitis C
Hepatitis Screenings Could Save Money, Lives
Study Reports Hepatitis C Impairs Cognitive Functioning: memory,
concentration, depression
Phlebotomy May Delay Progression of Liver Fibrosis in Chronic Hepatitis
C Patients
How Green Tea May Fight Inflammation
FDA Probes Anti-Anxiety Herb
July
2002
Study: Hepatitis C Patients Infected After
Age 30 Far More Likely to Develop Cirrhosis
Study: HAART Therapy Effective for Both
Hepatitis C and HIV Patients
Bayer Seeks FDA Approval of Hepatitis C
Test
Discovery Could One Day Lead to Genetic
Treatment for Hepatitis C, Other Diseases
Study Set of Use of Human Liver Cells to
Treat Cirrhosis Patients
Enbrel Helps Chronic Hepatitis C Patients
With Rheumatoid Arthritis
SELECTED
HIGHLIGHTS FROM THE DRAFT NIH HCV CONSENSUS STATEMENT
Roche's
Hepatitis-C Drug Pegasys Gets EU Approval
Rigel to Present Update on Hepatitis
C Drug Development Program
Par Pharmaceutical Announces Licensing of
Ribavirin From Three Rivers
Pharmaceutical-Anda Filing with
Paragraph IV Certification May Offer
Co-Exclusive Marketing Rights
August 2002
Review: New Edition of Living with
Hepatitis C Offers Chapter on Pegylated Interferons
Hepatitis E Vaccine Recommended For
Patients With Chronic Liver Disease
Hepatitis C May Cause Erectile
DysfunctionUpdate of Progress on New Drugs -
Including Albuferon for HCV
Clinical Trials of Monoclonal
Antibody for HCV
Interferon Helps Prevent Liver-Related
Deaths for Hepatitis C Patients
Chinese Drug Said Effective and Safe in
Treating Chronic Hepatitis C
Once-Promising Drug Found Ineffective in
Treating Hepatitis D
September 2002
Final NIH Consensus Statement
Read the final report recently issued on the NIH Consensus Development
Conference on the Management of Hepatitis C 2002. This important
document will drive current and future approaches to the management and
care of HCV.
The Business of Organ
Transplants
Researchers develop model to
predict post-transplant survival in liver transplant patients
New techniques may boost
tolerance of donor organs
Early Study Results Show New
Interferon Effective for Hepatitis C
Study Finding Pegylated
Interferon Superior Said Flawed
Maxim Advances Enrollment of
Ceplene Phase 2 Clinical Trial
Oklahoma Hospital Nurse
Reused Needles on Patients
GenOdyssee Announces
Positive Results of Proprietary Interferon-alpha Variants for the
Treatment of Hepatitis C and Cancer
Roche's ribavirin Copegus available in all EU Countries within months
Hepatitis C drug completes Mutual Recognition Procedure in the European
Union
Deaths of Hepatitis C
Patients in Japan Prompt Label Change in Rebetol
Pegasys + Ribavirin: study results
published
October 2002
6 Infected by Organ Donor
Battleground: Schering and
Roche Duke It Out Over the Huge Hepatitis C Market As Concerns Arise for
Some Patients
PEG-Intron Pen
Introduced in Europe
Injection Drug
Users Continue Risky Habits Even After Testing Positive for Hepatitis C
Virus
Acetaminophen
(Tylenol) Liver Damage "Is it safe for me to take Tylenol?"
VIRACEPT(R) Appears to be Generally Well
Tolerated In Hepatitis-C Co-Infected Patients
Herbal hope for liver disease
Chronic or Primary HCV Infection
Risk of GI
symptoms with over-the-counter nonsteroidal anti-inflammatory drugs
FDA Meeting May Mean Roadblock for
Roche
Warning Issued on Reuse of Needles
InterMune, Inhale
to develop hepatitis C drug
'Invisible Condom'
May Prevent HIV and Herpes
Device extends liver cancer
patients' lives-study
FDA Approves Pegasys
Spontaneous Recovery from Hepatitis C Infection Higher Than Thought
High proportion of untreated chronic hepatitis C patients suffers
emotional distress
2005-Pegylated form of Infergen
How many patients are being treated with interferon-based antiviral
therapies ?
March
2002
America's Blood Centers Supports FDA Approval Of Nucleic Acid Testing
ICN Pharmaceuticals Defends Ribavirin Patient
Maxim says drug can stop liver damage from alcohol
Flumazenil improves hepatic encephalopathy in patients with cirrhosis
Study: Better Quality of Life With Pegylated Interferon
EPA Approves Disinfectant to Fight Spread of Hepatitis B
Study: Hepatitis C Does Not Up Risk of Death in First 10 Years
Study: Wine Daily Ups Liver Cancer Risk for Hepatitis Patients
Study: Hepatitis C Patients Not on Antiviral Therapy More Depressed
Roche Expects Approval of Pegasys in 2002
US Panel Advises Tattooed and Pierced Not Give Blood
North Shore-LIJ Physician Is Lead Author of Hepatitis C
Study; Results
Indicate New Drug Therapy Improves Adherence and Cure Rate
New Molecular Tests Make It Easier to Measure Hepatitis Viral Load
New Research Encouraging on Hepatitis B Combination Therapy
Rivarin-High Dose Interferon Combination Improves Responses In Hepatitis
C
Pamela Anderson-Living with Hepatitis C
April
2002
Sharing Injection Equipment Spreads Hepatitis C
GenPhar Announces Novel Vaccines for HIV, Hepatitis B, Hepatitis C, and
Marburg Viruses
Doctor Called Likely Source of Hepatitis in Patients
Study: Low-Income Young Women in San Francisco Have High Hepatitis C
Rate
Study: Hepatitis A Vaccination Recommended for Hepatitis C Patients
α-Fetoprotein Levels Predictive of Hepatocellular Carcinoma Recurrence
Study confirms Importance of Interferon Sensitivity-Determining Region
in HCV Genotype 1 Responsiveness
Study: Smoking, Alcohol Increase Liver Problems for Hepatitis C Patients
Study: Transmission of Hepatitis C From Doctor to Patient "Rare"
New Study to Evaluate HAART in Treating Co-Infected Hepatitis C, HIV
Patients
Pegasys Plus Ribavirin Produces Highest Sustained Virological Response (SVR)
Rate Ever Achieved for Patients with HCV Genotype 1
Low White Blood Cell and Platelet Counts Are Common with HCV
HCV Activists Criticize Schering's "Access Assurance" Program for PEG-Intron
One of our own speaks out in Washington
May
2002
2002
HCV Related Plenary Highlights from DDW
May News Stories 2002
New Investigational Studies Report on CellCept Use in Patients Who Are
Re-Infected With Hepatitis C After a Liver Transplant
Hepatitis C Treatment
Slows Liver Damage
Ribozyme Pharmaceuticals
Announces Clinical Trials Update and Conference Call
Phase II Study of
Heptazyme Slowed Following Loss of Vision in an Animal
Study: PEG-Interferon
and Ribavirin Slow Liver Fibrosis in Hepatitis C Patients
Tacrolimus-Associated
Diabetes Has Hepatitis C Connection
Liver Disease Varies
With Age In Hepatitis C-Infected Drug Users
Patients
With Hepatitis C Must Be Discouraged From Drinking Alcohol
Markov Method Quantifies
Fibrosis Progression In Hepatitis C
Study: Lamivudine May
Delay Transplant Need for Some Hepatitis B Patients
6 Local Deaths Lead to
Plasma Warning
Severe Liver Disease Is
Uncommon Within the First 2 Decades of HCV Infection
June 2002
European Hepatitis C Patients Sought for
Phase II Trial of Ceplene in Combo Therapy
Study: Hereditary Hemochromatosis With
Hepatitis C Ups Risk of Cirrhosis and Fibrosis
Study: Shorter Induction Combo Therapy
Appears as Effective for Hepatitis C
Study: IND-6556 May Improve Liver Enzymes
in Some Hepatitis C Patients
Study: Peg-Intron Superior to Colchicine
for Hepatitis C Patients With Advanced Cirrhosis
Study: No Significant Difference in Side
Effects for Weight-Based Doses of Rebetol
Hepatitis C May Be Transmitted Via
Toothbrushes
Schering Canada Inc. - Pegetron(TM)
Receives Health Canada Approval for the
Treatment of Chronic Hepatitis C
January 2001
Hepatitis C Infection More Prevalent in
Lupus Patients Than Healthy Controls
Heavy Alcohol Use Greatly Increases Cirrhosis Risk in Hepatitis
C-Infected Patients
FDA Approves Hepatitis C Therapy
February 2001
Daily Interferon Alfacon-1 Treatment with
Ribavirin Appears Promising For HCV Infection
SciClone sees Zadaxin launch in U.S. end 2003, early 2004
HCV Viremia at Delivery a Risk Factor for Mother-to-Infant Transmission
March 2001
Drug helps depression during interferon
treatments
Titan Pharmaceuticals Initiates Clinical Testing of Pivanex(R) For
Hepatic Tumors
Human Genome Sciences Begins Phase I Clinical Trial of Albuferon in
Hepatitis C Patients
April 2001
ACG Clinical Implications: Hepatitis in the
New Millennium; Hepatitis C Monitoring Tests Advance with Treatment
Study Illuminates How Hepatitis C Infects Cells
Maxim Reports 72-Week Results From Completed Phase 2 Hepatitis C Study
Demonstrating Benefit of Treatment With Ceplene
Pegylated Interferon's, Improved Molecular Tools Brighten Potential
Outcomes for Patients With Hepatitis
May 2001
Schering-Plough Reports Interim Results of
PEG-INTRON(TM) Plus REBETOL(R) Studies in Hepatitis C Patients at
Digestive Diseases Week Meeting
Rate of Hepatitis C Liver Disease May Be More Rapid Than Previously
Indicated
PEGASYS(R) (peginterferon Alfa-2a) Studied in Post-Liver Transplant
Patients With Recurrent Hepatitis C Infection
Conference Report: Hepatitis C Infection -- Optimizing Treatment,
Patient Management, and Basic Aspects
June 2001
Interferon Prevents Liver Cancer, But Not
Mortality, In Hepatitis C Cirrhosis
Hepatitis C Virus Genotype Linked To Cirrhosis Transjugular renal biopsy
feasible for patients with liver disease
Antisense Drug Demonstrates Substantial Reduction Of Viral Load in
Patients With Drug Resistant Hepatitis C Virus
July 2001
Twice-Daily Interferon-Beta No Better Than
Once-Daily Dosing for Hepatitis C
Schering-Plough Announces FDA Approval to Market REBETOL(R) (Ribavirin,
USP) Capsules Separately For Use in Combination With INTRON(R) A for
Chronic Hepatitis C
Roche Licenses Potential Second-Generation Drug From ICN to Set New
Standards In Hepatitis C Treatment
XTL Biopharmaceuticals Initiates Phase I
Clinical Trial with XTL-002 for Hepatitis C
August 2001
Hepatitis C Subtype Determines Interferon
Responsiveness Factors
Bio-Rad Enters New Territories for Hepatitis C Testing: Company Expands
HCV License With Ortho/Chiron
Three Rivers Pharmaceuticals Seeks Permission For Generic Treatment for
Hepatitis C
September 2001
Daily High-Dose Interferon Induction Therapy Not Advantageous in
Hepatitis C
Peginterferon Regimen Outperforms Standard
Treatment for Chronic Hepatitis C
Some Blood Donors Get Bad News
Discovers Novel Hepatitis 'C' Target; Drug Development Program
October 2001
Quick Treatment Can Cure Hepatitis C
Drug May Limit Liver Damage Caused by Hepatitis C
"UNBUNDLED" REBETOL (RIBAVIRIN) FOR THE TREATMENT OF HEPATITIS C
New Treatment Stops Liver Scarring in Mice
November 2001
Maxim Pharmaceuticals to Initiate Phase 2
Clinical Trial of Ceplene in Triple Combination Therapy for Hepatitis C
Maxim Reports Results From Hepatitis C Pilot Study of Ceplene
Triple-Drug Therapy At AASLD Conference
BioMedicines Presents Promising Results from Phase II Trials Of Omega
Interferon for the Treatment of Hepatitis C
99% OF PATIENTS REMAIN FREE OF HEPATITIS C VIRUS WHEN TESTED THREE YEARS
LATER
Three Rivers Counter-Sues Schering Corporation Over Ribavirin
Effectiveness of Hepatitis C Drug Can Now Be Determined Sooner; VCU
Physician Co-Authors New Study Analysis, Says Findings May Improve
Patient Care
CN Presents New Data on Viramidine(TM) and Levovirin(TM) At The AASLD
Annual Meeting
Effects of the Human Genome Project in 2002
FDA Warns Against Dietary Supplement
December 2001
Risk of sexual transmission of HCV is low between spouses
Risk factors for the presence of varices in cirrhotic patients are
identified
HBV and HCV Prevalence is higher in Crohn's Patients
Acute leukemia can occur after liver transplantation
Ribavirin Antiviral Drug Works by Causing "Genetic Meltdown"
CD-Based Tool Boosts Rural Doctors' Comfort Level With Hepatitis C
Patients
Slowing diseases, New and Old
Genetic engineering and the world health crisis